NextGenSpatial Spatial Code of Tumors: Mapping, Modeling, and Mechanism
- Coordinator
- Weizmann Institute of Science, Israel
- Runs
- 1 August 2027 to 31 July 2032
- Status
- Running
- EU funding
- €1.5m
- Total cost
- €1.5m
- Partners
- 1 organisations in 1 countries
- Type
- European Research Council grant
- Grant agreement
- 101299384
What the project is doing
In the project's own words, from its summary on CORDIS.
Tumors are ecosystems, where malignant and non-malignant cells interact within an organized tumor microenvironment (TME). Understanding how these interactions drive complex pathology such as metastasis and response to treatment is a major challenge in cancer biology. While spatial proteomics technologies have begun to reveal the architectural complexity of human tumors, current approaches are limited in scale, standardization, and functional interpretability.
Existing platforms measure only dozens of proteins, analysis pipelines are fragmented, hindering cross-cohort integration, and functional studies rarely preserve the TME’s architecture. This project addresses the question: what are the spatially organized intercellular networks that govern therapeutic response and resistance in human tumors. To answer it, it proposes three interconnected aims to develop new technologies to map such networks at scale, interrogate them using a common modeling framework and perform mechanistic studies to elucidate their function.
In Aim 1, we will develop KiloPlex, a novel spatial proteomics method to image 1000 proteins in intact human tumors using combinatorial staining and AI-based decomposition. We will apply KiloPlex to profile 1000 tumors from 10 cancer types, generating a comprehensive spatial proteomics atlas with unprecedented molecular resolution. In Aim 2, we will build an AI foundation model trained on this data and existing data to enable generalizable analysis of tissue organization and cell-cell interactions across cancer types.
In Aim 3, we will couple spatial proteomics with ex vivo cultures to perturb and probe tumor-related immune populations and drug-targeted T cells, to understand their function in mediating response to checkpoint inhibitors. Together, these aims will establish a new framework for spatially resolved, functional tumor profiling, opening the door to informed biomarkers, therapeutic targets, and precision immunotherapy strategies.
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Weizmann Institute of Science | Rehovot | Israel | Coordinator |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI